The global non-viral transfection reagents market is expected to reach USD 633 million in 2023 anticipated to grow at a CAGR of 8.0% during the forecast period 2023-2035.

Nucleic acid-based therapeutic approaches have emerged as a robust modality in targeting genetic instructions for the treatment of various diseases. The demonstrable success of these therapies has led to a notable surge in regulatory approvals, underscoring their therapeutic potential and escalating acceptance within the medical community. Consequently, the imperative for efficient delivery systems, known as vectors, to transport these therapies has become increasingly pronounced.

Traditionally, viral vectors were the cornerstone for producing such therapies. However, despite substantial advancements in research and development, viral vectors present inherent limitations. Challenges encompass immune system responses, potential toxicity concerns, the exorbitant costs associated with their development, and constraints related to the quantity of genetic material they can effectively transport in a single instance.

To mitigate these challenges, there has been a paradigm shift towards non-viral gene delivery vehicles for transfection purposes. Non-viral transfection involves the targeted introduction of genetic material into diverse cells using carriers that are not of viral origin. In response to the escalating demand for nucleic acid-based therapies, novel non-viral transfection methods and systems are undergoing development, tailored explicitly to facilitate efficient intracellular delivery in laboratory settings. This surge in demand for non-viral vectors, coupled with the ongoing evolution of reagents and delivery systems, is poised to drive substantial and sustained growth within the market for these transformative technologies in the forecasted period.

Report Coverage
? An executive summary of the insights captured during our research. It offers a high-level view on the current state of non-viral transfection reagents and systems market and its likely evolution in the mid-long term.
? A general overview of non-viral transfection reagents and systems, highlighting details on transfection and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering.
? A detailed assessment of the overall market landscape of the companies developing non-viral transfection reagents, based on several relevant parameters, such as type of carrier used, compatible cell type, type of molecule delivered, and serum compatibility.
? An in-depth company competitiveness analysis of non-viral transfection reagent and system developers based in North America, Europe and Asia-Pacific. The analysis compares various developers based on supplier strength and product portfolio strength.
? A detailed technology competitiveness analysis of electroporation-based transfection systems and other non-viral transfection systems, taking into consideration the supplier strength and product portfolio strength.
? Tabulated profiles of key players engaged in the development of non-viral transfection reagents and systems (shortlisted based on the type of carrier used, compatible cell type, type of molecule delivered and serum compatibility). Each profile includes a brief overview of the company, financial information (if available), recent developments and an informed future outlook.
? An in-depth analysis of over 80 cell (including TCR and CAR-T cell) and gene therapy developers that are likely to partner with non-viral transfection reagent and system developers, based on several relevant parameters, such as pipeline maturity, developer strength, pipeline strength and type of therapy.
? A review of the various non-viral focused initiatives undertaken by big pharma players, featuring various insightful representations, based on year of initiative, type of initiative, type of therapy and target therapeutic area.
? An in-depth analysis of close to 900 patents that have been filed / granted related to non-viral transfection systems, since 2019, highlighting key trends associated with these patents, across type of patent, publication year, application year, geography, type of applicant, CPC symbols, emerging focus areas, leading players.
? An insightful framework to understand the pricing strategy of the non-viral transfection reagents offered by a company, along with its competitive position in the market. In addition, it presents the equation devised to calculate the likely price of non-viral transfection reagents based upon their characteristics.
? The likely distribution of the future opportunity across, non-viral transfection systems (chemical method and physical method ), end-user (academic and research institutions, pharmaceutical companies and other end-users), application area (clinical application and research application) and geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Key Market Companies
? Altogen Biosystems
? Bio-Rad Laboratories
? BEX
? BTX
? Celsion
? Genprex
? Inovio Pharmaceuticals
? MaxCyte
? MilliporeSigma
? Nepa Gene
? OZ Biosciences
? Thermo Fisher Scientific